Press release dated March 19, 2025, titled "Syngene concludes the acquisition of Biologics Manufacturing…
As filed · Syngene International Limited has informed the Exchange regarding a press release dated March 19, 2025, titled "Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioS
What happened
FactSyngene International Limited has informed the Exchange regarding a press release dated March 19, 2025, titled "Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.". 2015, please find enclosed the press release titled “Syngene concludes the acquisition of Biologics. Manufacturing Facility from Emergent BioSolutions Inc.”.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedQ4 growth was broad based across research, development and manufacturing services, underpinning full year growth of 4% on a reported basis and 2% in constant currency.
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business mom (management committed by FY26)
- We are maintaining our annual guidance for revenue for FY26. (management committed by FY26)
Evidence
- Syngene International Limited has informed the Exchange regarding a press release dated March 19, 2025, titled "Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.".(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- ACQUISITION base 74; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%